Psychoactive drug advertising: a comparison of technical information from three countries: Brazil, United States and United Kingdom

Detalhes bibliográficos
Autor(a) principal: Mastroianni,Patricia de Carvalho
Data de Publicação: 2005
Outros Autores: Galduróz,José Carlos Fernandes, Carlini,Elisaldo Araujo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: São Paulo medical journal (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000500002
Resumo: CONTEXT AND OBJECTIVE: Studies carried out in the 1970s and 1980s showed that there were country-dependent disparities in the information given for the same drug in medical advertisements. National and international regulations have been published to do away with such disparities and to foster the rational use of drugs. The purpose of this study was to compare the information contained in psychoactive drug advertisements published in psychiatric journals in Brazil, the United States and the United Kingdom, before and subsequent to the publication of the United States Export Act, in 1986, the WHO criteria, in 1988, and the Brazilian Sanitary Surveillance Agency Resolution no. 102, in 2000. TYPE OF STUDY AND SETTING: Content analysis, at Centro Brasileiro de Informações sobre Drogas Psicotrópicas (Cebrid). METHODS: We gathered advertisements from Brazilian, American and British psychiatry periodicals published before and after each ruling. We analyzed a total of twenty-four Brazilian advertisements that were for the same psychoactive drugs as advertised in American and/or British publications from the same period. RESULTS: We observed that Brazilian advertisements omitted information on usage restrictions, such as contraindications, adverse reactions, interactions, warnings and precautions, and that such information was present in American and British advertisements. CONCLUSIONS: The data suggest that disparities in the information given for the same drug still persist. The information depends on the country in which each drug is marketed. The legislation is insufficient for eradicating such disparities.
id APM-1_0eddb2bfaf977324a8af9d05c2af4599
oai_identifier_str oai:scielo:S1516-31802005000500002
network_acronym_str APM-1
network_name_str São Paulo medical journal (Online)
repository_id_str
spelling Psychoactive drug advertising: a comparison of technical information from three countries: Brazil, United States and United KingdomPharmaceutical preparationsPropagandaAdvertisingPsychotropic drugsLegislationCONTEXT AND OBJECTIVE: Studies carried out in the 1970s and 1980s showed that there were country-dependent disparities in the information given for the same drug in medical advertisements. National and international regulations have been published to do away with such disparities and to foster the rational use of drugs. The purpose of this study was to compare the information contained in psychoactive drug advertisements published in psychiatric journals in Brazil, the United States and the United Kingdom, before and subsequent to the publication of the United States Export Act, in 1986, the WHO criteria, in 1988, and the Brazilian Sanitary Surveillance Agency Resolution no. 102, in 2000. TYPE OF STUDY AND SETTING: Content analysis, at Centro Brasileiro de Informações sobre Drogas Psicotrópicas (Cebrid). METHODS: We gathered advertisements from Brazilian, American and British psychiatry periodicals published before and after each ruling. We analyzed a total of twenty-four Brazilian advertisements that were for the same psychoactive drugs as advertised in American and/or British publications from the same period. RESULTS: We observed that Brazilian advertisements omitted information on usage restrictions, such as contraindications, adverse reactions, interactions, warnings and precautions, and that such information was present in American and British advertisements. CONCLUSIONS: The data suggest that disparities in the information given for the same drug still persist. The information depends on the country in which each drug is marketed. The legislation is insufficient for eradicating such disparities.Associação Paulista de Medicina - APM2005-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000500002Sao Paulo Medical Journal v.123 n.5 2005reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/S1516-31802005000500002info:eu-repo/semantics/openAccessMastroianni,Patricia de CarvalhoGalduróz,José Carlos FernandesCarlini,Elisaldo Araujoeng2005-12-08T00:00:00Zoai:scielo:S1516-31802005000500002Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2005-12-08T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse
dc.title.none.fl_str_mv Psychoactive drug advertising: a comparison of technical information from three countries: Brazil, United States and United Kingdom
title Psychoactive drug advertising: a comparison of technical information from three countries: Brazil, United States and United Kingdom
spellingShingle Psychoactive drug advertising: a comparison of technical information from three countries: Brazil, United States and United Kingdom
Mastroianni,Patricia de Carvalho
Pharmaceutical preparations
Propaganda
Advertising
Psychotropic drugs
Legislation
title_short Psychoactive drug advertising: a comparison of technical information from three countries: Brazil, United States and United Kingdom
title_full Psychoactive drug advertising: a comparison of technical information from three countries: Brazil, United States and United Kingdom
title_fullStr Psychoactive drug advertising: a comparison of technical information from three countries: Brazil, United States and United Kingdom
title_full_unstemmed Psychoactive drug advertising: a comparison of technical information from three countries: Brazil, United States and United Kingdom
title_sort Psychoactive drug advertising: a comparison of technical information from three countries: Brazil, United States and United Kingdom
author Mastroianni,Patricia de Carvalho
author_facet Mastroianni,Patricia de Carvalho
Galduróz,José Carlos Fernandes
Carlini,Elisaldo Araujo
author_role author
author2 Galduróz,José Carlos Fernandes
Carlini,Elisaldo Araujo
author2_role author
author
dc.contributor.author.fl_str_mv Mastroianni,Patricia de Carvalho
Galduróz,José Carlos Fernandes
Carlini,Elisaldo Araujo
dc.subject.por.fl_str_mv Pharmaceutical preparations
Propaganda
Advertising
Psychotropic drugs
Legislation
topic Pharmaceutical preparations
Propaganda
Advertising
Psychotropic drugs
Legislation
description CONTEXT AND OBJECTIVE: Studies carried out in the 1970s and 1980s showed that there were country-dependent disparities in the information given for the same drug in medical advertisements. National and international regulations have been published to do away with such disparities and to foster the rational use of drugs. The purpose of this study was to compare the information contained in psychoactive drug advertisements published in psychiatric journals in Brazil, the United States and the United Kingdom, before and subsequent to the publication of the United States Export Act, in 1986, the WHO criteria, in 1988, and the Brazilian Sanitary Surveillance Agency Resolution no. 102, in 2000. TYPE OF STUDY AND SETTING: Content analysis, at Centro Brasileiro de Informações sobre Drogas Psicotrópicas (Cebrid). METHODS: We gathered advertisements from Brazilian, American and British psychiatry periodicals published before and after each ruling. We analyzed a total of twenty-four Brazilian advertisements that were for the same psychoactive drugs as advertised in American and/or British publications from the same period. RESULTS: We observed that Brazilian advertisements omitted information on usage restrictions, such as contraindications, adverse reactions, interactions, warnings and precautions, and that such information was present in American and British advertisements. CONCLUSIONS: The data suggest that disparities in the information given for the same drug still persist. The information depends on the country in which each drug is marketed. The legislation is insufficient for eradicating such disparities.
publishDate 2005
dc.date.none.fl_str_mv 2005-11-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000500002
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000500002
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1516-31802005000500002
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Paulista de Medicina - APM
publisher.none.fl_str_mv Associação Paulista de Medicina - APM
dc.source.none.fl_str_mv Sao Paulo Medical Journal v.123 n.5 2005
reponame:São Paulo medical journal (Online)
instname:Associação Paulista de Medicina
instacron:APM
instname_str Associação Paulista de Medicina
instacron_str APM
institution APM
reponame_str São Paulo medical journal (Online)
collection São Paulo medical journal (Online)
repository.name.fl_str_mv São Paulo medical journal (Online) - Associação Paulista de Medicina
repository.mail.fl_str_mv revistas@apm.org.br
_version_ 1754209261272956928